Tempus AI announces launch of its Fuses program
Tempus AI (TEM) announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Why Tempus AI Stock Soared 15% Today
Tempus AI was targeted by a short seller last week. Since then, the company has made several announcements that have helped quell doubts introduced by the short report. TD Cowen maintained its buy rating today. 10 stocks we like better than Tempus Ai › Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) jumped 0.4% and 0.6%, respectively. Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report last week alleging, among other things, that Tempus is overstating its use of AI. On Friday and Saturday, the company made announcements regarding two AI-driven programs. Whether the timing was deliberate or not, the announcements appeared to help quell doubts introduced by the short seller allegations. Tempus One, the company's AI platform that is intended to help physicians make better decisions, got a key update. The company announced Saturday that the platform will now have direct access to electronic health records (EHR) systems. As the company describes it, the expanded access to data allows the platform to "capture real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams." On Friday, the company announced an initiative it calls Fuses. The company says it will use its vast amount of clinical data to create "an AI-enabled diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality." Today, investors were also pleased to see that TD Cowen is maintaining its buy rating, unconvinced by the short seller's allegations. Despite this, and the company's recent announcements, I believe that Tempus' stock is currently overvalued even if the short seller's allegations don't hold up. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Tempus AI Stock Soared 15% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Why Tempus AI, Inc. (TEM) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other top-performing stocks on Monday. Tempus AI extended its winning streak to a third consecutive day on Monday, jumping 15.02 percent to close at $63.47 apiece as investors snapped up shares after earning a 'buy' recommendation despite being hit by a negative short-seller report. On Monday, TD Cowen maintained its 'buy' recommendation on Tempus AI, Inc.'s (NASDAQ:TEM), pricing it at $62, albeit lower than its latest closing price. The recommendation followed Spruce Point Capital's report on the company, saying it sees a '50 to 60 percent potential long-term downside and market underperformance risk.' Photo by CDC on Unsplash 'We believe the Tempus equity growth story is built on hype and appeal to retail investors that it is an exciting and disruptive technology play with AI appeal, which could have the next Tesla or Nvidia-type inflection,' Spruce Point was quoted as saying. For its part, Tempus AI, Inc. (NASDAQ:TEM) said that it would not respond to a report 'riddled with hypotheticals and inaccuracies.' 'We remain focused on delivering shareholder value, taking advantage of the enormous opportunity of bringing AI to healthcare, and helping patients live longer and healthier lives,' it said. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 days ago
- Yahoo
Why Tempus AI, Inc. (TEM) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other top-performing stocks on Monday. Tempus AI extended its winning streak to a third consecutive day on Monday, jumping 15.02 percent to close at $63.47 apiece as investors snapped up shares after earning a 'buy' recommendation despite being hit by a negative short-seller report. On Monday, TD Cowen maintained its 'buy' recommendation on Tempus AI, Inc.'s (NASDAQ:TEM), pricing it at $62, albeit lower than its latest closing price. The recommendation followed Spruce Point Capital's report on the company, saying it sees a '50 to 60 percent potential long-term downside and market underperformance risk.' Photo by CDC on Unsplash 'We believe the Tempus equity growth story is built on hype and appeal to retail investors that it is an exciting and disruptive technology play with AI appeal, which could have the next Tesla or Nvidia-type inflection,' Spruce Point was quoted as saying. For its part, Tempus AI, Inc. (NASDAQ:TEM) said that it would not respond to a report 'riddled with hypotheticals and inaccuracies.' 'We remain focused on delivering shareholder value, taking advantage of the enormous opportunity of bringing AI to healthcare, and helping patients live longer and healthier lives,' it said. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
